Loading
A phase 1/2 trial of Pembrolizumab in salivary gland cancers and non-small-cell lung cancer, run by VM Oncology, LLC, now recruiting.
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma is a phase 1/2 interventional study registered as NCT03556228 by VM Oncology, LLC, with 242 participants planned, started 2018-06-08 and due to reach its primary completion in 2027-12. Interventions recorded: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg). Conditions listed: Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Salivary gland cancers, Head and neck squamous cell carcinoma.
Shares Mesothelioma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
Shares Salivary gland cancers, Head and neck squamous cell carcinoma.
Shares Mesothelioma, Immune checkpoint inhibitors.
Shares Mesothelioma, Non-small-cell lung cancer.
Shares Mesothelioma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Mesothelioma, Non-small-cell lung cancer.
Shares Mesothelioma, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/